Amphera Gears Up To Evaluate Dendritic Cells For Pleural Mesothelioma
Dutch biotech Amphera has progressed into late-stage clinical studies with dendritic cells activated with an allogeneic lysate of tumor cell lines; the dendritic cells are expected to have a therapeutic effect in patients with mesothelioma, a tumor with few treatment options.
You may also be interested in...
Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.